Table 1 Summary of HGF/Met alterations in breast cancer
From: The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Reference | Observations/lesions | Clinical/biological aspects |
|---|---|---|
Yao and colleagues [21] | High levels of HGF in breast tumor tissue | Invasive ductal carcinomas |
Tuck and colleagues [16] | HGF/Met autocrine loop in tumor cells | Co-localization at the advancing margins of the tumors |
Jin and colleagues [22] | High levels of HGF and c-Met overexpression in breast tissue | Invasive ductal carcinomas |
Camp and colleagues [24] | Met overexpression | Reduced survival, relapse and metastatic dissemination |
Edakuni and colleagues [23] | Met overexpression | High histological grade, proliferative index, advancing margins |
Kang and colleagues [82] | High levels of Met and HGF in node-negative breast cancer | Tumor progression and poor patient outcome |
Lengyel and colleagues [83] | Met overexpression in node-positive breast cancer | Disease progression and decrease in disease-free survival |
Charafe-Jauffre and colleagues [43] | Met overexpression in breast cancer cell lines | Basal-like phenotype |
Lindemann and colleagues [84] | Imbalance in Met expression between tumor and normal tissue | Aggressive ductal carcinoma in situ |
Eichbaum and colleagues [85] | High HGF serum levels | Liver metastatic colonization from breast cancer |
Garcia and colleagues [45] | Met overexpression in tissue microarrays | Poor prognosis, basal-like phenotype |
Finkbeiner and colleagues [49] | Transcriptional upregulation of Met | Anchorage-independent growth of basal-like breast cancer cells |
Smolen and colleagues [65] | Met amplification in a Brca1-p53 mouse model of breast cancer | Mouse mammary tumor progression |
Ponzo and colleagues [53] | MMTV-Met mutant transgenic mice | Heterogeneous mammary tumors, basal-like phenotype |
Graveel and colleagues [52] | Met mutant knock-in mice | Mammary tumors associated with basal-like phenotype |